Hearing loss--risk factor for cisplatin ototoxicity? Observations
Related Experiment Videos
J D Durrant1, G Rodgers, E N Myers
1Department of Otolaryngology, University of Pittsburgh, PA.
The American Journal of Otology
|September 1, 1990
Abstract:
Ototoxicity associated with cisplatin chemotherapy is well established, but opinion is split regarding the relative risk associated with preexisting hearing loss. The emerging consensus is that pretreatment loss does not increase the risk of cisplatin ototoxicity. Results from a preliminary study of a small sample from our patient population supports this consensus.